Akebia Therapeutics Inc. (AKBA) is priced at $3.11 after the most recent trading session. At the very opening of the session, the stock price was $3.07 and reached a high price of $3.25, prior to closing the session it reached the value of $3.05. The stock touched a low price of $2.97.
Recently in News on January 6, 2021, Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference. Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Bioconnect 2021 Conference, which takes place virtually January 11 – 14, 2021. You can read further details here
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
Akebia Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $3.25 on 01/13/21, with the lowest value was $2.76 for the same time period, recorded on 01/04/21.
Akebia Therapeutics Inc. (AKBA) full year performance was -54.93%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Akebia Therapeutics Inc. shares are logging -77.32% during the 52-week period from high price, and 48.80% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $2.09 and $13.71.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 16740172 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Akebia Therapeutics Inc. (AKBA) recorded performance in the market was 11.07%, having the revenues showcasing -12.39% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 445.13M, as it employees total of 360 workers.
Specialists analysis on Akebia Therapeutics Inc. (AKBA)
During the last month, 0 analysts gave the Akebia Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 3.52, with a change in the price was noted -7.73. In a similar fashion, Akebia Therapeutics Inc. posted a movement of -71.31% for the period of last 100 days, recording 7,349,455 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for AKBA is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.24.
Trends and Technical analysis: Akebia Therapeutics Inc. (AKBA)
Raw Stochastic average of Akebia Therapeutics Inc. in the period of last 50 days is set at 72.36%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 72.73%. In the last 20 days, the company’s Stochastic %K was 64.12% and its Stochastic %D was recorded 63.83%.
Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 11.07%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -74.82%, alongside a downfall of -54.93% for the period of the last 12 months. The shares increased approximately by 4.01% in the 7-day charts and went down by 8.36% in the period of the last 30 days. Common stock shares were lifted by -12.39% during last recorded quarter.